Zealand Pharma A/S (0NZU.IL)
| Previous close | 230.50 |
| Open | 232.00 |
| Bid | 228.60 x 0 |
| Ask | 240.20 x 0 |
| Day's range | 232.00 - 236.60 |
| 52-week range | 70.05 - 241.80 |
| Volume | |
| Avg. volume | 19,794 |
| Market cap | 12.241B |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -20.62 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Company announcement – No. 8 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 34,594 divided into 34,594 new shares with a nominal value of DKK 1 each. The increa
- GlobeNewswire
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396In development as a non-incretin peptide therapy for the potential management of overweight and obesity Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on t
- GlobeNewswire
Zealand Pharma Provides Update on Silicon Valley Bank Closure
Company announcement – No. 6 / 2023 Zealand Pharma Provides Update on Silicon Valley Bank Closure Update to company announcement No.5 following joint statement by U.S. Treasury, Federal Reserve, and FDIC: Depositors at SVB will have access to all of their money starting Monday, March 13Zealand now expects to recover all of its deposits held at SVB, Monday March 13 Copenhagen, Denmark March 13, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the disc
